Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279362 | 0.95 | PRKCA (0.47) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2279364 | 0.92 | PRKCA (0.44) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3685055 | 0.90 | PRKCA (0.57) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL4223402 | 0.90 | PRKCA (0.57) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2281723 | 0.89 | PRKCA (0.59) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3685264 | 0.89 | PRKCA (0.59) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL4206442 | 0.87 | PRKCA (0.37) | PRKCAMMP12 | |
| SCHEMBL2275224 | 0.85 | PRKCA (0.49) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL2277321 | 0.84 | PRKCA (0.35) | PRKCAMMP12 | |
| SCHEMBL4213234 | 0.84 | PRKCA (0.57) | PRKCAMMP12NR1I2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | claimed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | claimed |
| EP-3043865-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036442-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-03-19 | — | — | WO | disclosed |
| US-7989438-B2 | Therapeutic compounds | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-02 | — | — | US | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | PRKCA 4250/4885MMP12 2067/4885NR1I2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.